Neuron-Glial2 (NG2) cells: A promising target for neuroinflammation-related neurodegeneration

Neuron-glial 2 (NG2) cells, or polydendrocytes, are dynamic glial cells in the central nervous system (CNS) that contribute to neuroinflammation and neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. These cells interact with neurons, astrocytes, and microglia, modulating inflammatory responses, synaptic activity, and blood-brain barrier integrity. While NG2 cells have protective roles, their aberrant activation can contribute to scarring, inflammation, and neuronal degeneration. This narrative review synthesizes current literature on the molecular and functional properties of NG2 cells with a focus on their involvement in neuroinflammation and neurodegeneration. Relevant studies were identified through searches in PubMed, Scopus, and Google Scholar, using keywords such as “NG2 cells,” “neuroinflammation,” and “neurodegenerative diseases.” Articles were selected based on relevance to NG2 cell biology, their interactions with other glial cells, and their therapeutic implications. Findings were categorized into key themes, including NG2 cell activation, inflammatory signaling, and potential therapeutic targets. NG2 cells are key players in neuroinflammation and neurodegeneration, serving both protective and pathological roles. Understanding their mechanisms of action can aid in identifying therapeutic strategies targeting NG2 cell activation, including anti-inflammatory agents, epigenetic modulators, natural compounds, and monoclonal antibodies. Future research should explore NG2 cell-targeted interventions to develop novel treatments for CNS disorders. • NG2 cells act as both protectors and contributors to neuroinflammation in neurodegeneration. • Targeting NG2 cells with anti-inflammatory agents, epigenetic regulators, and advanced biotechnological tools offer new therapeutic potential. • Future research should focus on NG2-specific interventions to uncover mechanisms and develop therapies for neurodegeneration.